Kouhkan Azam, Hosseini Roya, Baradaran Hamid Reza, Arabipoor Arezoo, Cheraghi Rezvan, Moini Ashraf, Malekzadeh Farideh, Khamseh Mohammad
Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran. Email:
Department of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Int J Fertil Steril. 2022 Aug 21;16(3):172-179. doi: 10.22074/ijfs.2021.522566.1070.
This study aimed to determine the prevalence of postpartum metabolic syndrome (MetS), glucose intolerance,
and the determinants, 6-12 weeks postpartum in women with assisted reproduction technology conception
gestational diabetes mellitus diagnosis (ART-GDM) compared to women with spontaneous conception and GDM
diagnosis (SC-GDM).
Materials and Methods: In this prospective cohort study, two groups consisting of 62 ART-GDM and 64 SC-GDM
singleton pregnant women were followed 6-12 weeks after delivery for postpartum MetS. Fasting glucose, 75-g 2-h
OGTT, and lipid profile were assessed. Waist and hip circumference, and systolic and diastolic blood pressures (BP)
were measured at postpartum. Clinical, paraclinical, and obstetric data were recorded from registry offices. The prevalence
of MetS and glucose intolerance were determined. Predictors of MetS and glucose intolerance were evaluated
by logistic regression.
Results: The prevalence of postpartum MetS was 20.8% in ART-GDM women and 10.9% in SC-GDM (P=0.123).
Mean postpartum BMI and systolic BP were significantly higher in the ART-GDM group (P=0.016 and P=0.027
respectively). Adverse pregnancy outcomes were significantly higher in the ART-GDM group. Postpartum glucose
intolerance prevalence did not vary significantly between the groups. Family history of diabetes was a predictive factor
for postpartum MetS and glucose intolerance 6-12 weeks after delivery.
Conclusion: Early postpartum MetS and glucose intolerance prevalence after assisted conception did not vary significantly;
however, postpartum body mass index (BMI) and systolic BP were significantly higher in the ART-GDM group.
Lifestyle modification programs and long-term health care of ART women with GDM diagnosis can be recommended.
Further studies with larger sample size and longer follow-up are necessary to verify our findings.
本研究旨在确定与自然受孕并诊断为妊娠期糖尿病（SC-GDM）的女性相比，辅助生殖技术受孕并诊断为妊娠期糖尿病（ART-GDM）的女性在产后6-12周时产后代谢综合征（MetS）、糖耐量异常的患病率及其决定因素。
在这项前瞻性队列研究中，两组分别由62例ART-GDM和64例SC-GDM单胎孕妇组成，产后6-12周对她们进行产后MetS随访。评估空腹血糖、75克2小时口服葡萄糖耐量试验（OGTT）和血脂谱。产后测量腰围和臀围以及收缩压和舒张压（BP）。从登记处记录临床、辅助检查和产科数据。确定MetS和糖耐量异常的患病率。通过逻辑回归评估MetS和糖耐量异常的预测因素。
ART-GDM组产后MetS的患病率为20.8%，SC-GDM组为10.9%（P=0.123）。ART-GDM组产后平均体重指数和收缩压显著更高（分别为P=0.016和P=0.027）。ART-GDM组不良妊娠结局显著更高。两组间产后糖耐量异常患病率无显著差异。糖尿病家族史是产后6-12周时产后MetS和糖耐量异常的预测因素。
辅助受孕后早期产后MetS和糖耐量异常患病率无显著差异；然而，ART-GDM组产后体重指数（BMI）和收缩压显著更高。可以推荐对诊断为GDM的ART女性进行生活方式改变计划和长期医疗保健。有必要进行更大样本量和更长随访时间的进一步研究以验证我们的发现。
